Search

Displaying results 3641 - 3650 of 5900 in total
  1. Drug

    Ombitasvir

    go.drugbank.com/drugs/DB09296
    ApprovedInvestigational

    The barrier for develoment of resistance to NS5A inhibitors is lower than that of NS5B inhibitors, another class of DAAs [A19593]. … Ombitasvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

  2. Drug

    Cintredekin besudotox

    go.drugbank.com/drugs/DB05305
    Investigational

    Cintredekin besudotox is made from a human protein, Interleukin 13 (IL13), linked to a bacterial toxin, _Pseudomonas exotoxin_ (PE). The IL13 portion binds to receptors on the tumor. … Cintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual

  3. Drug

    Phenserine

    go.drugbank.com/drugs/DB04892
    Investigational

    Axonyx announced on 20 September 2005 that phenserine was ineffective in two curtailed phase 3 trials. … If this is substantiated in an ongoing clinical trial then phenserine may open the door to an entirely new type of treatment for AD.

  4. Drug

    Maxy-G34

    go.drugbank.com/drugs/DB05718
    Investigational

    wild type human G-CSF to avoid PEGylation of such sites. … This was accomplished by removing the three lysine residues at positions 16, 34 and 40, and replacing them with arginine, and substituting two new lysine residues at positions 105 and 159.

  5. Drug

    Bavituximab

    go.drugbank.com/drugs/DB05136
    Investigational

    Bavituximab is a chimeric Anti-PS monoclonal antibody analog which is used to potentially treat cancers and viral infections. … It binds to phosphatidylserine and other exposed host cell lipids when induced by cellular stress. Additional analogs in the class include 3G4, 2aG4, 9d2 and Hu3g4.

  6. Drug

    Cetilistat

    go.drugbank.com/drugs/DB06586
    Investigational

    Cetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.

  7. Drug

    CYT007-TNFQb

    go.drugbank.com/drugs/DB05758
    Experimental

    CYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis. … The vaccine should allow for administration of low amounts of drug to individual patients (in the microgram range) and for convenient dosing schedules.

  8. Drug

    Anacaulase

    go.drugbank.com/drugs/DB17449
    ApprovedInvestigational

    It is mostly composed (80-95% w/w) of proteins such as stem bromelain, ananain, jacalin-like lectin, bromelain inhibitors, and phytocystatin inhibitor, as well as saccharides, as both free monosaccharides … Therefore, enzymatic alternatives such as anacaulase can lead to better clinical outcomes.

  9. Drug

    Rilapladib

    go.drugbank.com/drugs/DB05119
    Investigational

    Rilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development.

  10. Drug

    INS 316

    go.drugbank.com/drugs/DB05390
    Experimental

    It is selective P2y2 receptor antagonists claimed to be useful as anti-inflammatory agents. … INS316 belongs to the family of drugs called nucleoside triphosphates.It is studied in the diagnosis of lung diseases, including lung cancer.